US 8501191
FGFR2-IIIb fusion proteins and methods of making them
granted A61KA61K45/06A61P
Quick answer
US patent 8501191 (FGFR2-IIIb fusion proteins and methods of making them) held by Five Prime Therapeutics, Inc. expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Five Prime Therapeutics, Inc.
- Grant date
- Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61K, A61K45/06, A61P, A61P1/02, A61P1/04